Dr. Stéphanie BECKER

Année d’arrivée au Centre


Parcours professionnel

  • Praticien hospitalier, Centre Henri Becquerel, Rouen
  • Assistant Hospitalo-Universitaire, Centre Eugène Marquis, Rennes
  • Assistant Hospitalo-Universitaire et interne, Institut Jean Godinot, Reims


  • Thèse de sciences, Université Rennes 1
  • Thèse de médecine, Faculté de médecine de Reims
  • DES de médecine nucléaire, Faculté de médecine de Reims
  • DEA, Université Rennes 1

Interventions pratiquées ou expertise

  • Imagerie TEP et lymphomes
  • Traitement des lésions hépatiques par sphères radiomarquées à l’90Y
  • Imagerie TEP et cancer du poumon

Sociétés savantes

  • LYSA-image, groupe Maladie de Hodgkin (radiothérapie et médecine nucléaire)

Publications majeures

  • Dosimetric evaluation and therapeutic response to internal radiation therapy of hepatocarcinomas using iodine-131-labelled lipiodol. Nuc Med Comm 2008, 29: 815-825.
  • Increased lipiodol uptake in hepatocellular carcinoma possibly due to increased membrane fluidity by dexamethasone and tamoxifen. Nucl Med Biol 2010, 37 : 777-784
  • S. Becker, N Lepareur, V Cadeillan, V Ardisson, S Bayat, N Noiret, E Garin. “Optimization of hepatocarcinoma uptake with radiolabeled lipiodol: development of new lipiodol formulations with increased viscosity.” Cancer Biother Radiopharm. 2012 ; 27 : 149-55.
  • Bevacizumab enhances efficiency of radiotherapy in a lung adenocarcinoma rodent model: Role of αvβ3 imaging in determining optimal window. Nucl Med Biol. 2015 Dec; 42(12):923-30.
  • Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):2034-2041.
  • Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL-Response. Clin Cancer Res. 2016 Jul 1; 22(13):3414-5.
  • Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma. Clin Cancer Res. 2016 Aug 1; 22(15):3801-9.
  • Baseline Total Metabolic Tumor Volume Measured with Fixed or Different Adaptive Thresholding Methods Equally Predicts Outcome in Peripheral T Cell Lymphoma. J Nucl Med. 2017 Feb; 58(2):276-281.
  • Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging. 2018 May; 45(5): 680-688.
  • Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio. PLoS One. 2019 Feb 7;14(2):e0211649.